Cover Image
市場調查報告書

神經母細胞瘤:開發平台分析

Neuroblastoma - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229754
出版日期 內容資訊 英文 383 Pages
訂單完成後即時交付
價格
Back to Top
神經母細胞瘤:開發平台分析 Neuroblastoma - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 383 Pages
簡介

所謂神經母細胞瘤是腎上腺、頸部、胸部、脊椎的神經組織、神經脊細胞產生的癌,大部分患者都是嬰幼兒。一般是發生在腎上腺,之後轉移到人體其他部位。容易罹病的危險因子包含了遺傳。主要的症狀有腹部·胸部的腫塊,及噁心、骨骼疼痛、呼吸困難、黑眼圈、移動困難等。診斷時常用到X光掃描影像檢查和電腦斷層掃描、核磁共振攝影、切片檢查、尿液檢查等。使用化療和放射治療、幹細胞移植、單株抗體等醫藥療法有控制病情的可能性。

本報告提供全球各國治療神經母細胞瘤(Neuroblastoma)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

神經母細胞瘤概要

治療藥的開發

  • 神經母細胞瘤開發中產品:概要
  • 神經母細胞瘤開發中產品:比較分析

各企業開發中的神經母細胞瘤治療藥

大學/研究機關研究中的神經母細胞瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

神經母細胞瘤治療藥:開發中的產品一覽(各企業)

神經母細胞瘤治療藥:研究中的產品一覽(各大學/研究機關)

神經母細胞瘤治療藥的開發企業

  • Ability Pharmaceuticals, S.L.
  • Acetylon Pharmaceuticals, Inc.
  • Advanced Accelerator Applications S.A.
  • Ampio Pharmaceuticals, Inc.
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Bellicum Pharmaceuticals, Inc.
  • Bexion Pharmaceuticals, LLC. .
  • BioLineRx, Ltd.
  • Bionucleon Srl
  • Biotec Pharmacon ASA
  • Cebiotex, S.L.
  • Celgene Corporation
  • 中外製藥
  • Cleveland BioLabs, Inc.
  • CorMedix Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • DEKK-TEC, Inc.
  • EnGeneIC Ltd
  • Errant Gene Therapeutics, LLC
  • GlaxoSmithKline Plc
  • Green Cross Cell Corporation
  • Ignyta, Inc.
  • Incuron, LLC
  • Juno Therapeutics Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lindis Biotech GmbH
  • MabVax Therapeutics Holdings, Inc
  • MediaPharma s.r.l.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Morphogenesis, Inc.
  • Novartis AG
  • Novogen Limited
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Progenics Pharmaceuticals, Inc.
  • Recombio S.L
  • Ribomic Inc.
  • Sareum Holdings Plc
  • 鹽野義製藥
  • Syros Pharmaceuticals, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tiltan Pharma Ltd.

神經母細胞瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

神經母細胞瘤治療藥:開發中產品的最新趨勢

神經母細胞瘤治療藥:暫停開發的產品

神經母細胞瘤治療藥:中止開發的產品

神經母細胞瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7996IDB

Summary

Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H1 2016', provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
  • The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects
  • The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Neuroblastoma Overview
  • Therapeutics Development
  • Neuroblastoma - Therapeutics under Development by Companies
  • Neuroblastoma - Therapeutics under Investigation by Universities/Institutes
  • Neuroblastoma - Pipeline Products Glance
  • Neuroblastoma - Products under Development by Companies
  • Neuroblastoma - Products under Investigation by Universities/Institutes
  • Neuroblastoma - Companies Involved in Therapeutics Development
  • Neuroblastoma - Therapeutics Assessment
  • Drug Profiles
  • Neuroblastoma - Recent Pipeline Updates
  • Neuroblastoma - Dormant Projects
  • Neuroblastoma - Discontinued Products
  • Neuroblastoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuroblastoma, H1 2016
  • Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Neuroblastoma - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
  • Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2016
  • Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2016
  • Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016
  • Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2016
  • Neuroblastoma - Pipeline by Bionucleon Srl, H1 2016
  • Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2016
  • Neuroblastoma - Pipeline by Cebiotex, S.L., H1 2016
  • Neuroblastoma - Pipeline by Celgene Corporation, H1 2016
  • Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
  • Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H1 2016
  • Neuroblastoma - Pipeline by CorMedix Inc., H1 2016
  • Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2016
  • Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2016
  • Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2016
  • Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Neuroblastoma - Pipeline by Green Cross Cell Corporation, H1 2016
  • Neuroblastoma - Pipeline by Ignyta, Inc., H1 2016
  • Neuroblastoma - Pipeline by Incuron, LLC, H1 2016
  • Neuroblastoma - Pipeline by Juno Therapeutics Inc., H1 2016
  • Neuroblastoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2016
  • Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
  • Neuroblastoma - Pipeline by MediaPharma s.r.l., H1 2016
  • Neuroblastoma - Pipeline by MEI Pharma, Inc., H1 2016
  • Neuroblastoma - Pipeline by Merck & Co., Inc., H1 2016
  • Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Morphogenesis, Inc., H1 2016
  • Neuroblastoma - Pipeline by Novartis AG, H1 2016
  • Neuroblastoma - Pipeline by Novogen Limited, H1 2016
  • Neuroblastoma - Pipeline by Pfizer Inc., H1 2016
  • Neuroblastoma - Pipeline by Pharmacyclics, Inc., H1 2016
  • Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Recombio S.L, H1 2016
  • Neuroblastoma - Pipeline by Ribomic Inc., H1 2016
  • Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2016
  • Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Neuroblastoma - Pipeline by Syros Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Neuroblastoma - Pipeline by Tiltan Pharma Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Neuroblastoma - Dormant Projects, H1 2016
  • Neuroblastoma - Dormant Projects (Contd..1), H1 2016
  • Neuroblastoma - Dormant Projects (Contd..2), H1 2016
  • Neuroblastoma - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Neuroblastoma, H1 2016
  • Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top